Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,486 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02882659 | Dendritic Killer Cell-based Immunotherapy for Solid Tumors | unknown | Phase 1 | 18 | FullHope Biomedical Co., Ltd.INDUSTRY | 0 | Aug 30, 2016 | clinicaltrials |
| A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 |
| 42 |
| Merrimack PharmaceuticalsINDUSTRY |
| 2 |
| Aug 4, 2016 |
| clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT02399735 | Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | unknown | Phase 1 | 18 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | unknown | Phase 1 | 112 | e-Therapeutics PLCINDUSTRY | 4 | Apr 6, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02586285 | Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma | unknown | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02587884 | Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | unknown | Phase 1 | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02403544 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT00669136 | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | terminated | Phase 1 | 2 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | terminated | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 2, 2015 | clinicaltrials |
| NCT02578602 | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | completed | Phase 1 | 26 | University of Southern CaliforniaOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT01348503 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma | terminated | Phase 1 | 5 | Indiana UniversityOTHER | 1 | Aug 31, 2015 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00997022 | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | completed | Phase 1 | 14 | Columbia UniversityOTHER | 1 | Aug 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01801163 | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 | 0 | Indiana UniversityOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01914263 | Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection | unknown | Phase 1 | 40 | Alliancells-PuRui Biocience Co., Ltd.INDUSTRY | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT00844168 | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | completed | Phase 1 | 4 | University of WashingtonOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT01462903 | A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors | unknown | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT00976170 | Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | completed | Phase 1 | 42 | Chugai PharmaceuticalINDUSTRY | 2 | Oct 3, 2014 | clinicaltrials |
| NCT00978107 | Trial of TG4023 Combined With Flucytosine in Liver Tumors | completed | Phase 1 | 16 | TransgeneINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01540461 | Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) | completed | Phase 1 | 17 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT01721941 | TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Scripps Clinic Cancer CenterOTHER | 1 | Jul 4, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 8 | Pierluigi PorcuOTHER | 1 | Dec 3, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2016source: clinicaltrials